Compare Schlumberger NV (SLB) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Twist Bioscience Corp — how do they compare? Schlumberger NV trades at $48.95 (market cap $72.69B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Schlumberger NV is far larger — about 7.2× Twist Bioscience Corp's market cap, and Schlumberger NV pays a 2.41% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Twist Bioscience Corp for 27 Days on average.
| SLB | TWST | |
|---|---|---|
Market Cap | $72.69B | $10.08B |
Volume | 16,228,451 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $60.10 | $205.00 |
52-Week Low | $31.72 | $25.45 |
Typical Hold Time | 99 Days | 27 Days |
Enterprise Value | $81.42B | $10.01B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $48.98, up 2.13% today, with a bearish technical signal despite recent earnings beats. The company secured major contracts in Oman and Mozambique, expanding its international footprint. Revenue declined slightly to $35.71B in 2025, with net income margin at 8.53%. Analyst consensus remains strongly bullish with 85% buy ratings and a $64.58 price target, representing 32% upside potential.
SLB faces near-term headwinds from declining profit margins and bearish technical indicators, but strong contract wins and analyst optimism suggest long-term growth potential. Key risks include oil price volatility and execution challenges in new markets. The stock offers value at current levels for investors with a medium-to-long-term horizon.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
